Abstract
The need for non-invasive assessment of airway inflammation is imperative, since inflammatory airway diseases, such as asthma and COPD, are characterized by variation in their clinical presentation throughout their course. Exhaled breath condensate (EBC) collection represents a rather appealing method that can be used to conveniently and noninvasively collect a wide range of volatile and non-volatile molecules from the respiratory tract, without affecting airway function or inflammation. Although promising, EBC is currently used only as a research tool, due to the lack of appropriate standardization and the absence of reference values. A large number of mediators of inflammation, oxidative and nitrosative stress, including adenosine, ammonia, hydrogen peroxide, isoprostanes, leukotrienes, prostanoids, nitrogen oxides, peptides and cytokines, have been studied in EBC. This review focuses mainly on the presentation of the above biomarkers in asthma as well as on the effect of various factors on their concentrations. Concentrations of such mediators have been shown to be related to the underlying asthma and its severity and to be modulated by therapeutic interventions. Despite the encouraging positive results up-to-date, the introduction of EBC in everyday clinical practice requires the work-out of some methodological pitfalls, the standardization of EBC collection, and finally the identification of a reliable biomarker which is reproducible, has normal values and provides information for the underlying inflammatory process and the response to treatment. So far none of the parameters studied in EBC fulfils the aforementioned requirements.
Keywords: Exhaled breath condensate, asthma, biomarkers, clinical applications, condensate, airway inflammation, non-volatile molecules, volatile molecules, hyperresponsiveness, hydrocarbons
Current Medicinal Chemistry
Title: Exhaled Breath Condensate in Asthma: From Bench to Bedside
Volume: 18 Issue: 10
Author(s): S. Loukides, K. Kontogianni, G. Hillas and I. Horvath
Affiliation:
Keywords: Exhaled breath condensate, asthma, biomarkers, clinical applications, condensate, airway inflammation, non-volatile molecules, volatile molecules, hyperresponsiveness, hydrocarbons
Abstract: The need for non-invasive assessment of airway inflammation is imperative, since inflammatory airway diseases, such as asthma and COPD, are characterized by variation in their clinical presentation throughout their course. Exhaled breath condensate (EBC) collection represents a rather appealing method that can be used to conveniently and noninvasively collect a wide range of volatile and non-volatile molecules from the respiratory tract, without affecting airway function or inflammation. Although promising, EBC is currently used only as a research tool, due to the lack of appropriate standardization and the absence of reference values. A large number of mediators of inflammation, oxidative and nitrosative stress, including adenosine, ammonia, hydrogen peroxide, isoprostanes, leukotrienes, prostanoids, nitrogen oxides, peptides and cytokines, have been studied in EBC. This review focuses mainly on the presentation of the above biomarkers in asthma as well as on the effect of various factors on their concentrations. Concentrations of such mediators have been shown to be related to the underlying asthma and its severity and to be modulated by therapeutic interventions. Despite the encouraging positive results up-to-date, the introduction of EBC in everyday clinical practice requires the work-out of some methodological pitfalls, the standardization of EBC collection, and finally the identification of a reliable biomarker which is reproducible, has normal values and provides information for the underlying inflammatory process and the response to treatment. So far none of the parameters studied in EBC fulfils the aforementioned requirements.
Export Options
About this article
Cite this article as:
Loukides S., Kontogianni K., Hillas G. and Horvath I., Exhaled Breath Condensate in Asthma: From Bench to Bedside, Current Medicinal Chemistry 2011; 18 (10) . https://dx.doi.org/10.2174/092986711795328418
DOI https://dx.doi.org/10.2174/092986711795328418 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Structure, Function, Involvement in Diseases and Targeting of 14-3-3 Proteins: An Update
Current Medicinal Chemistry Derivatives of IL-16 to Modulate Airway Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Supercritical Fluid Chromatographic Method for Montelukast: Application in Content Uniformity and Degradation Study
Current Analytical Chemistry Evaluation of the Anthelmentic Activity of Garlic (Allium sativum) in Mice Naturally Infected with Aspiculuris tetraptera
Recent Patents on Anti-Infective Drug Discovery Neutrophils and Eosinophils: Clinical Implications of their Appearance, Presence and Disappearance in Asthma and COPD
Current Drug Targets - Inflammation & Allergy Prostaglandin EP Receptor Subtypes Involved in Regulating HCO3- Secretion from Gastroduodenal Mucosa
Current Pharmaceutical Design Anti-Tumor Necrosis Factor-Alpha (TNF-α) Treatment Strategies in Crohns Disease
Recent Patents on Inflammation & Allergy Drug Discovery A Stress Repair Mechanism That Maintains Vertebrate Structure During Stress
Cardiovascular & Hematological Disorders-Drug Targets <i>Zanthoxylum bungeanum</i> Seed Oil Elicits Autophagy and Apoptosis in Human Laryngeal Tumor Cells via PI3K/AKT/mTOR Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Recent Patents on Proteases and Kinases as Anti-Infective Agents: A Review
Recent Patents on Anti-Infective Drug Discovery Pharmacogenomics of Asthma
Current Pharmaceutical Design Recent Advances in Controlled Release Pulmonary Therapy
Current Drug Delivery Mast Cells as a Double Edged Sword in Immunity: Disorders of Mast Cell Activation and Therapeutic Management. Second of Two Parts
Endocrine, Metabolic & Immune Disorders - Drug Targets The Clinical and Immunological Features of Patients with Primary Antibody Deficiencies
Endocrine, Metabolic & Immune Disorders - Drug Targets Selection of Potential Pharmacological Targets in ALS Based on Whole- Genome Expression Profiling
Current Medicinal Chemistry Inflammation in Coronary Artery Disease and Acute Myocardial Infarction - is the Stage Set for Novel Therapies?
Current Pharmaceutical Design CARING (CAncer Risk and INsulin analoGues): The Association of Diabetes Mellitus and Cancer Risk with Focus on Possible Determinants - A Systematic Review and a Meta-Analysis
Current Drug Safety CD38 as a Regulator of Cellular NAD: A Novel Potential Pharmacological Target for Metabolic Conditions
Current Pharmaceutical Design The Role of Tregs in Cancer: Foxp3 as a Putative Target for Therapy
Current Signal Transduction Therapy Patent Selections:
Current Biomarkers (Discontinued)